Sanofiās test drug to treat moderate-to-severe asthma fails to meet goalsĀ
HQ Team April 17, 2025: Sanofi S.A.ās drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 17, 2025: Sanofi S.A.ās drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.
By K. Leelamoni November 5, 2023: Outbreaks ofĀ pneumoniaĀ affecting children in parts of northern China, the US,Ā the Netherlands, and Denmark are higher than.
The World Health Organization is monitoring an increase in childrenās illness caused by pathogens, including acute respiratory syndrome coronavirus 2, in northern China.
HQ Team September 23, 2023: An advisory panel of the national public agency of the US, Centers for Disease Control and Prevention, has.
HQ Team June 9, 2023: An advisory committee of the USFDA has given a āfavourable benefit-risk profileā for Sanofi and AstraZenecaās experimental drug.